TCR/CD3 activation and co-stimulation combined in one T cell retargeting system improve anti-tumor immunity.
We have recently described a novel modular targeting platform for T cell recruitment that not only efficiently replaces but also is superior to conventional T cell-engaging bispecific antibodies as it allows for the flexible targeting of several antigens and the delivery of co-stimulatory ligands to malignant lesions, thereby enhancing the antitumor potential of redirected T cells.
Institute of Immunology; Medical Faculty 'Carl Gustav Carus'; TU Dresden; Dresden, Germany.
Marc
M
Cartellieri
Institute of Immunology; Medical Faculty 'Carl Gustav Carus'; TU Dresden; Dresden, Germany.
Claudia
C
Arndt
Institute of Immunology; Medical Faculty 'Carl Gustav Carus'; TU Dresden; Dresden, Germany ; Institute of Radiopharmaceutical Cancer Research; Helmholtz-Zentrum Dresden-Rossendorf; Dresden, Germany.
Anja
A
Feldmann
Medical Clinic and Polyclinic I; University Hospital 'Carl Gustav Carus'; TU Dresden; Dresden, Germany.
Malte
M
von Bonin
Institute of Immunology; Medical Faculty 'Carl Gustav Carus'; TU Dresden; Dresden, Germany.
Eva-Maria
EM
Ewen
Institute of Immunology; Medical Faculty 'Carl Gustav Carus'; TU Dresden; Dresden, Germany.
Stefanie
S
Koristka
Institute of Immunology; Medical Faculty 'Carl Gustav Carus'; TU Dresden; Dresden, Germany.
Irene
I
Michalk
Institute of Immunology; Medical Faculty 'Carl Gustav Carus'; TU Dresden; Dresden, Germany.
Slava
S
Stamova
Institute of Immunology; Medical Faculty 'Carl Gustav Carus'; TU Dresden; Dresden, Germany.
Nicole
N
Berndt
Institute of Immunology; Medical Faculty 'Carl Gustav Carus'; TU Dresden; Dresden, Germany.
Anne
A
Gocht
Medical Clinic and Polyclinic I; University Hospital 'Carl Gustav Carus'; TU Dresden; Dresden, Germany.
Martin
M
Bornhäuser
Medical Clinic and Polyclinic I; University Hospital 'Carl Gustav Carus'; TU Dresden; Dresden, Germany.
Gerhard
G
Ehninger
Institute of Immunology; Medical Faculty 'Carl Gustav Carus'; TU Dresden; Dresden, Germany ; Center for Regenerative Therapies Dresden; TU Dresden; Dresden, Germany.
Marc
M
Schmitz
Institute of Immunology; Medical Faculty 'Carl Gustav Carus'; TU Dresden; Dresden, Germany ; Institute of Radiopharmaceutical Cancer Research; Helmholtz-Zentrum Dresden-Rossendorf; Dresden, Germany ; Center for Regenerative Therapies Dresden; TU Dresden; Dresden, Germany.
Michael
M
Bachmann
CD137; CD33; T-cell retargeting; acute myeloid leukemia; co-stimulatory ligands; immunotherapy; modular targeting system; single-chain bispecific antibodies